Drug intelligence / Profile preview

miR-124

Development stage
Unknown
Lead developer
Viridian Therapeutics
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous, Intrathecal
01

Overview

miR-124 is a highly conserved, brain-enriched microRNA that serves as a critical regulator of neuronal differentiation and a potent tumor suppressor. In the central nervous system, it maintains the quiescent state of neural stem cells and promotes their maturation into neurons. In oncology, particularly in glioblastoma multiforme (GBM), miR-124 is frequently downregulated, which contributes to increased tumor stemness, invasiveness, and resistance to therapy. As a therapeutic agent, miR-124 mimics or viral vectors are used to restore its expression, thereby post-transcriptionally repressing a network of oncogenic targets including **Lhx-2**, **CDK6**, and **STAT3**. This restoration inhibits the maintenance of glioma stem cells (GSCs) and suppresses epithelial-mesenchymal transition (EMT). Beyond oncology, miR-124 is investigated for its anti-inflammatory properties, as it modulates the cholinergic anti-inflammatory pathway and is a key mediator in the mechanism of action for drugs like obefazimod in inflammatory bowel disease.

Other names
microRNA-124microRNA124microRNA 124miR-124-3pmiR124-3pmiR 124-3p
02

Targets

LHX2CDK6 (Cyclin-dependent kinase 6)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on miR-124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-124.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call